Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy

Journal of Urology

Volumn 171, Issue 2 I, 2004, Pages 679-683

  Kojima, Satoko ^a   Suzuki, Hiroyoshi ^a   Akakura, Koichiro ^a   Shimbo, Masaki ^a   Ichikawa, Tomohiko ^a   Ito, Haruo ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Androgen antagonists; Hormone replacement therapy; Prostatic neoplasms; Substance withdrawal syndrome; Survival rate

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0345868307     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000106190.32540.6c     Document Type: Article

References (20)

1. Levi, F., Lucchini, F., Negri, E., Boyle, P. and La Vecchia, C.: Changed trends of cancer mortality in the elderly. Ann Oncol, 12: 1467, 2001
2. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet, 355: 1491, 2000
3. Schmitt, B., Wilt, T. J., Schellhammer, P. F., DeMasi, V., Sartor, O., Crawford, E. D. et al: Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology, 57: 727, 2001
4. Kelly, W. K. and Scher, H. I.: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol, 149: 607, 1993
5. Nieh, P. T.: Withdrawal phenomenon with the antiandrogen casodex. J Urol, 153: 1070, 1995
6. Gomella, L. G., Raj, G. V. and Moreno, J. G.: Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol, 158: 326, 1997
7. Akakura, K., Akimoto, S., Ohki, T. and Shimazaki, J.: Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology, 45: 700, 1995
8. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K. et al: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med, 332: 1393, 1995
9. Suzuki, H., Akakura, K., Komiya, A., Aida, S., Akimoto, S. and Shimazaki, J.: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate, 29: 153, 1996
10. Buchanan, G., Greenberg, N. M., Scher, H. I., Harris, J. M., Marshall, V. R. and Tilley, W. D.: Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res, 7: 1273, 2001
11. Palmberg, C., Koivisto, P., Kakkola, L., Tammela, T. L. J., Kallioniemi, O. P. and Visakorpi, T.: Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol, 164: 1992, 2000
12. Scher, H. I., Zhang, Z. F., Nanus, D. and Kelly, W. K.: Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology, 47: 61, 1996
13. Scher, H. I., Liebertz, C., Kelly, W. K., Mazumdar, M., Brett, C., Schwartz, L. et al: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol, 15: 2928, 1997
14. Desai, A., Stadler, W. M. and Vogelzang, N. J.: Nilutamide: possible utility as a second-line hormonal agent. Urology, 58: 1016, 2001
15. Joyce, R., Fenton, M. A., Rode, P., Constantine, M., Gaynes, L., Kolvenbag, G. et al: High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol, 159: 149, 1998
16. Gerber, G. S. and Chodak, G. W.: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. J Urol, 144: 1177, 1990
17. Harmanker, P., Hutter, R. V. P., Sobin, L. H. and Wager, G. and Witteking, Ch.: Prostate. In: TNM Atlas, 4th ed. New York: Springer Verlag, p. 272, 1997
18. Suzuki, H., Ueda, T., Ichikawa, T. and Ito, H.: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer, 10: 209, 2003
19. Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M. et al: Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res, 63: 149, 2003
20. Scher, H. I., Steineck, G. and Kelly, W. K.: Hormone-refractory (D3) prostate cancer: refining the concept. Urology, 46: 142, 1995